Business, energy, technology, markets and global industry news from Business News Today

complement pathway

PharmaDeviceNews complement pathway
Representative image of neuroimmunology research as Sanofi’s riliprubart Phase 3 trial halt puts CIDP treatment, complement inhibition, and rare neurology drug development under sharper focus.
Pharma & Biotech

Sanofi riliprubart setback puts VITALIZE trial and CIDP strategy under sharper focus

Find out how Sanofi’s riliprubart Phase 3 trial halt could reshape CIDP drug development and complement inhibition strategy.

Read More
Representative image illustrating transplant‑associated thrombotic microangiopathy, a life‑threatening complication after hematopoietic stem cell transplantation that is now the focus of new FDA‑approved treatment advances by Omeros Corporation.
Pharma & Biotech

Omeros secures FDA approval for YARTEMLEA, the first therapy for transplant-associated TA-TMA

FDA approves YARTEMLEA for TA-TMA. Find out how Omeros’ new drug could change transplant care for children and adults alike.

Read More